Accelerate collaboration and partnering across neurology and psychiatry pipelines and technologies, to reduce risk, validate technologies, and deliver better biodistribution of safe and efficacious molecules to the CNS


URLs:
Tickets: https://go.evvnt.com/2758081-0?pid=91
Brochure: https://go.evvnt.com/2758081-2?pid=91

Prices:
On the door - Vendor Pricing: USD 5499.00,
On the door - Biotech, Pharma and Investors: USD 2979.00,
On the door - Academics: USD 2399.00

Speakers: Antony Mattesich, Chief Executive Officer, Amphista, Dan Elbaum Chief Scientific Officer QurAlis, David Donabedian Executive Partner Longwood Fund, Eliseo Salinas Head of Research and Development Delix, Jenny Laird Vice President, Search and Evaluation Neuroscience Eli Lilly, John Mayfield Senior Vice President, Business Development and Strategy Flagship Pioneering, Jonathan Levenson Chief Scientific Officer FireCyte Therapeutics, Laxminarayan Bhat Founder, President and Chief Executive Officer Reviva Pharma, Maria Maccecchini Founder, President and CEO Annovis, Mathias Schmidt CEO | Executive Fellow ArmaGen | JCR Pharmaceuticals, Michaela Tolman Senior Director, Pipeline Strategic Planning Pfizer, Murali Gopalakrishnan Global Head, Neuroscience Search and Evaluation, Corporate Strategy AbbVie , Sam Alworth Co-Founder and Chief Executive Officer AcuraStem, Shaheen Lakhan Chief Medical Officer Click Therapeutics, Stacie Weninger President F-Prime Capital, Vidya Nadar Director, Search and Evaluation, Rare and Neurological Disorders Sanofi, Neel Desai Executive Director, Business Development Biogen , Alan Fu CFO IASO Biotechnology, Irena Melnikova Partner Pfizer Ventures, Catherine Abbadie External Innovation Lead Biogen, Sam Bannister Co-founder and Chief Scientific Officer Psylo Bio